These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1384 related articles for article (PubMed ID: 32029455)

  • 1. PARP and PARG inhibitors in cancer treatment.
    Slade D
    Genes Dev; 2020 Mar; 34(5-6):360-394. PubMed ID: 32029455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of poly(ADP-ribose) polymerase-1 or poly(ADP‑ribose) glycohydrolase individually, but not in combination, leads to improved chemotherapeutic efficacy in HeLa cells.
    Feng X; Koh DW
    Int J Oncol; 2013 Feb; 42(2):749-56. PubMed ID: 23254695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting poly(ADP-ribose) glycohydrolase to draw apoptosis codes in cancer.
    Tanuma SI; Shibui Y; Oyama T; Uchiumi F; Abe H
    Biochem Pharmacol; 2019 Sep; 167():163-172. PubMed ID: 31176615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific killing of DNA damage-response deficient cells with inhibitors of poly(ADP-ribose) glycohydrolase.
    Gravells P; Grant E; Smith KM; James DI; Bryant HE
    DNA Repair (Amst); 2017 Apr; 52():81-91. PubMed ID: 28254358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies.
    Li Y; Liu CF; Rao GW
    Curr Med Chem; 2021; 28(8):1565-1584. PubMed ID: 32164505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA replication stress and emerging prospects for PARG inhibitors in ovarian cancer therapy.
    Pillay N; Brady RM; Dey M; Morgan RD; Taylor SS
    Prog Biophys Mol Biol; 2021 Aug; 163():160-170. PubMed ID: 33524442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PARG Inhibitors and Functional PARG Inhibition Models.
    Sasaki Y; Hozumi M; Fujimori H; Murakami Y; Koizumi F; Inoue K; Masutani M
    Curr Protein Pept Sci; 2016; 17(7):641-653. PubMed ID: 27817742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors.
    Pillay N; Tighe A; Nelson L; Littler S; Coulson-Gilmer C; Bah N; Golder A; Bakker B; Spierings DCJ; James DI; Smith KM; Jordan AM; Morgan RD; Ogilvie DJ; Foijer F; Jackson DA; Taylor SS
    Cancer Cell; 2019 Mar; 35(3):519-533.e8. PubMed ID: 30889383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) - Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy.
    Harrision D; Gravells P; Thompson R; Bryant HE
    Front Mol Biosci; 2020; 7():191. PubMed ID: 33005627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poly(ADP-ribosyl)ation in relation to cancer and autoimmune disease.
    Masutani M; Nakagama H; Sugimura T
    Cell Mol Life Sci; 2005 Apr; 62(7-8):769-83. PubMed ID: 15868402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PARP and PARG inhibitors--new therapeutic targets in cancer treatment.
    Fauzee NJ; Pan J; Wang YL
    Pathol Oncol Res; 2010 Dec; 16(4):469-78. PubMed ID: 20383759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
    Lau CH; Seow KM; Chen KH
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.
    Boussios S; Abson C; Moschetta M; Rassy E; Karathanasi A; Bhat T; Ghumman F; Sheriff M; Pavlidis N
    Drugs R D; 2020 Jun; 20(2):55-73. PubMed ID: 32215876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disrupted ADP-ribose metabolism with nuclear Poly (ADP-ribose) accumulation leads to different cell death pathways in presence of hydrogen peroxide in procyclic Trypanosoma brucei.
    Schlesinger M; Vilchez Larrea SC; Haikarainen T; Narwal M; Venkannagari H; Flawiá MM; Lehtiö L; Fernández Villamil SH
    Parasit Vectors; 2016 Mar; 9():173. PubMed ID: 27007296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deletion of the nuclear isoform of poly(ADP-ribose) glycohydrolase (PARG) reveals its function in DNA repair, genomic stability and tumorigenesis.
    Min W; Cortes U; Herceg Z; Tong WM; Wang ZQ
    Carcinogenesis; 2010 Dec; 31(12):2058-65. PubMed ID: 20926829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE; Kennedy RD
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer.
    Zheng F; Zhang Y; Chen S; Weng X; Rao Y; Fang H
    Biomed Pharmacother; 2020 Mar; 123():109661. PubMed ID: 31931287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review on mechanisms of resistance to PARP inhibitors.
    Desai C; Pathak A; Limaye S; Maniar V; Joshi A
    Indian J Cancer; 2022 Mar; 59(Supplement):S119-S129. PubMed ID: 35343196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitotic functions of poly(ADP-ribose) polymerases.
    Slade D
    Biochem Pharmacol; 2019 Sep; 167():33-43. PubMed ID: 30910692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 70.